Sign In

Kevin Hambly

Biopharma Corporate Development Executive

Kevin Hambly is an accomplished biotechnology corporate development and strategic leader with over 20 years of experience.

He has a strong track record leading value-creating partnership/M&A/financing efforts spanning preclinical through commercial stage therapeutics and technology platforms.

Kevin has served as a BD lead for negotiation, execution, and alliance management for business development transactions worth over $4B total deal value.

His expertise includes corporate development, business development, strategic partnerships, licensing, M&A, corporate strategy, financing, corporate communications, investor relations, and alliance management.

In terms of education, Kevin pursued a Master of Business & Science (MBS) in Biotechnology/Strategy/Pharmaceutical Development at Keck Graduate Institute.

He also holds a BS in Biochemistry & Cellular/Molecular Biology from Western Washington University.

Throughout his career, Kevin has held key positions at reputable organizations such as ProfoundBio, Eliem Therapeutics, Nutcracker Therapeutics, Alder BioPharmaceuticals, Inc., Catalent Biologics/Redwood Bioscience, Seagen, and Eidogen/Eidogen-Sertanty.

Kevin Hambly
Add to my network

Location

Greater Seattle Area